Bildnachweis: Luma Vision, Bayern Kapital.
The medical technology company Luma Vision specialises in interventional cardiology procedures, offering cutting-edge hardware, software, and data science solutions for the treatment of cardiac arrhythmias and structural heart disease. Its proprietary Verafeye platform is a novel all-in-one 4D navigation and imaging system developed specifically for interventional applications in cardiology.
The platform employs a proprietary catheter sensor in combination with digital imaging and advanced processing and machine learning to provide high-resolution 360-degree images of the beating heart and the surrounding anatomy. ‘The system is a unique end-toend platform for personalised interventions, enabled by high-resolution real-time data generated directly within the catheter laboratory,’ says Dr Christoph Hennersperger, Co-Founder and Chief Technology Officer. Verafeye is a complete solution for navigation and imaging, meaning physicians do not need to use other systems for guidance during the procedure. ‘Up to four different modalities can be removed from the procedure, which significantly enhances efficiency,’ explains Hennersperger. Additionally, physicians receive intuitive and precise navigation data, tissue information, and AI-powered analytics in real-time to support successful interventions.
Market entry in the United States
‘The Munich site of Luma Vision is a key driver for the company’s technological development,’ says Monika Steger, Managing Director of Bayern Kapital. ‘A large part of the team here is working on the continuous improvement of the platform – while creating highly skilled jobs in Bavaria.’ All of this makes Luma Vision, from Bayern Kapital’s perspective, a particularly attractive investment in the field of innovative medical technology – and a prime example of a company whose headquarters may be outside Bavaria but whose substantial value creation in the state makes it eligible for investment, says Steger.
Locations in Munich and Dublin
Following its foundation with locations in Germany and Ireland, Luma Vision has developed the first generation of the Verafeye system from the ground up since it closed a first series A financing round in June 2020. In March 2025, the system received approval as a medical device in the USA. The gradual market entry in the United States is currently being prepared, with the next product version planned for early 2026. Hennersperger explains: ‘The first five sites have already been identified, and commercialisation at these locations is being prepared for early 2026.’ Alongside the commercialisation of the Verafeye platform, Luma Vision has established strategic partnerships with leading medical institutions, research organisations, clinicians, and technology partners. ‘In this environment, we are working on future product versions, which from mid-2026 will, among other things, enable the application in the area of left atrial appendage closure and subsequently also cover further areas of structural heart disease (tricuspid valve replacement and repair),’ says Hennersperger.
Investors wanted!
Luma Vision is currently in discussions regarding a new financing round. ‘On the one hand, the aim is to expand the product’s capabilities – for example, through the integration of additional functions such as navigation. On the other hand, the technology is to be applied to further medical conditions, such as structural heart diseases including valve replacement,’ says Steger. Finally, the technology is to be substantiated by robust clinical data. Initial successful studies have already been completed in this context.
